Novel regulation of neuronal genes implicated in Alzheimer disease by microRNA

S: 1. Long, JM, Kaefer, M and Packer, CS. In search of non-adrenergic non-cholinergic (NANC) neurotransmitters in rat bladder. EB 2003 Late-Breaking Abstracts p28, 2003; Awarded a Ribbon for Excellence at the National Sigma Xi Student Conference, 2003; Accepted for presentation at the 2004 National Conference on Undergraduate Research. 2. Long, JM, Kaefer, M and Packer, CS. Agonists of protease-activated receptors (PAR 1, PAR 2 and PAR 4) do not appear to be mediators of NANC contractions in rat bladder. Selected as one of 12 Finalists for the 2004 David S Bruce Excellence in Undergraduate Research Award, The FASEB J 18: A1083, 2004. 3. Packer, CS, Long, JM and Kaefer, M. Possible role of hydrogen peroxide (H2O2) in bladder dysfunction. The FASEB J 18: A1083, 2004. 4. Long, JM, Kaefer, M and Packer, CS. Non-adrenergic, non-cholinergic (NANC) contractions in rat and human urinary bladder. Northwest Urological Society meetings, Vancouver, Canada, 2004, and The FASEB J 19: A122, 2005. 5. Sokol D, Long JM, Maloney BR, Chen D, and Lahiri DK. Potential Alzheimer’s Disease Markers for Autism? Beta-Amyloid Precursor Protein and Acetylcholinesterase Correlate with Aggression in Autism. P02.010. Abstracts2View. Seattle, WA: Annual Meeting of the American Association of Neurology, 2009. Online. 6. Ray B, Gaskins DL, Long JM, and Lahiri DK. Acute restraint stress decreases neurotrophic factors (BDNF & GDNF) and presynaptic protein syntaxin in rat cortex and its relevance in neurodegeneration. Program No. 739.21. 2008 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, 2008. Online. 7. Long JM and Lahiri DK. Testing microRNA as a novel target for Alzheimer disease – miR-101 regulates levels of amyloid precursor protein (APP). Program No. 427.13. 2009 Neuroscience Meeting Planner. Chicago, IL: Society for Neuroscience, 2009. Online. 8. Long JM and Lahiri DK. Novel Specific MicroRNAs in Regulating Neuronal Genes Implicated In Alzheimer's Disease. Alzheimers Dement 6(4 Supplement 1): e13, 2010. 9. Lahiri DK, Bailey JA, Ray B, Tanila H, Banerjee P, and Long, JM. The effect of memantine and rivastigmine on synaptic markers and amyloid processing in cell culture and animal models of Alzheimer’s disease. Alzheimers Dement 6(4 Supplement 1): S581–S582, 2010. 10. Long JM and Lahiri DK. A novel target for Alzheimer disease: miR-101 regulates levels of Amyloid Precursor Protein. Session II, Abstract 41. 25 Annual National MD/PhD Student Conference Abstract Book. Keystone, CO: National MD/PhD Student Conference, 2010. 11. Ray B, Bailey JA, Long JM, Pathak Y, Sambamurti K, Rogers JT, Greig NH, Maitra A, and Lahiri DK. Historical journey of the application and use of curcumin from culinary purposes to therapeutics in neurodegenerative disorders. Program No 27.21. 2010 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience, 2010. Online 12. Long JM and Lahiri DK. Role of specific microRNAs in regulating neuronal genes implicated in Alzheimer disease. Program No. 424.1. 2010 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience, 2010. Online 13. Lahiri DK, and Long JM. Discovery of a novel drug target for Alzheimer’s disease: miR-101 regulates levels of the amyloid precursor protein. Session IL-90. Dubai, UAE: 3 International Conference on Drug Discovery and Therapy. Curr Med Chem (Special Abstract Issue): 32, 2011. 14. Lahiri DK, Ray B, Chauhan N, Bailey JA, and Long JM. SAC (S-allyl-cysteine) as a novel therapeutic agent for Alzheimer’s disease (AD) based on studies from neuronal cultures and APP-transgenic model for AD. Session PO-164. Dubai, UAE: 3 International Conference on Drug Discovery and Therapy. Curr Med Chem (Special Abstract Issue): 174, 2011. 15. Ray B, and Long JM, Sokol DK, Lahiri DK. Biochemical evidence for the dysregulation of Alzheimer’s amyloid precursor protein (APP) expression and metabolism in fragile X syndrome (FXS) and severe autism. To be presented at the 66 Annual meeting of the Society of Biological Psychiatry, San Francisco, CA, 2011. 16. Lahiri DK, Ray B, Bailey JA, and Long JM. Early-life environment and epigenetics in Alzheimer's disease: A new paradigm represented by the LEARn model. Presented at the 66 Annual meeting of the Society of Biological Psychiatry, San Francisco, CA, 2011. 17. Long JM and Lahiri DK. A novel microRNA interaction relevant to Alzheimer’s disease pathogenesis and drug target discovery: miR-346 induces expression of amyloid precursor protein. Alzheimers Dement 7 (4 Supplement 1): S566–S567, 2011. MANUSCRIPTS: 1. Long JM and Lahiri DK. MicroRNA-101 downregulates Alzheimer’s amyloid-β precursor protein levels in human cell cultures and is differentially expressed. Biochem Biophys Res Commun (404): 889–895, 2011. 2. Sokol DK, Maloney BR, Long JM, Ray B, and Lahiri DK. Autism, Alzheimer’s Disease and Fragile X: APP, FMRP and mGluR5 are molecular links. Neurology 76(15):1344–1352, 2011. 3. Ray B*, Long JM*, Sokol DK, and Lahiri DK. Increased secreted amyloid precursor protein-α (sAPPα) in severe autism: Proposal of a specific anabolic pathway and biomarker. PLoS ONE 6(6): e20405, 2011. 4. Long JM and Lahiri DK. Current drug targets for modulating Alzheimer’s amyloid precursor protein: role of specific microRNA species. Curr Med Chem 18(22): 3314– 3321, 2011. 5. Long JM and Lahiri DK. Advances in MicroRNA experimental approaches to study physiological regulation of gene products implicated in CNS disorders. Exp Neurol 235(2): 402–418, 2012 6. Long JM, Ray B and Lahiri DK. MicroRNA-153 Physiologically Inhibits Expression of Amyloid-β Precursor Protein in Cultured Human Fetal Brain Cells and is Dysregulated in a Subset of Alzheimer Disease Patients. J Biol Chem 287(37):31298–31310, 2012. *Co-first author